Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

AG Edwards Starts Bioenvision at Buy

From Standard & Poor's Equity Research

AG Edwards started covering Bioenvision (BIVN) at buy, noting that clofarabine is at the beginning of a long lifecycle with potential to address a broad spectrum of cancers.

Analyst Aaron Reames says clofarabine is a second generation purine nucleoside analogue in development to treat adult and pediatric leukemias, lymphomas, and solid tumors. Reames says clofarabine is designed to combine most favorable properties of two of the most commonly used chemotherapies: fludarabine and cladribine. The analyst cautions that the company is only appropriate for speculative investors that can tolerate a high degree of risk, as Bioenvision is not expected to be profitable until 2008.

blog comments powered by Disqus